Cor Vasa 2017, 59(3):e251-e256 | DOI: 10.1016/j.crvasa.2016.11.007

Bioabsorbable stents in routine practice. New epoch in interventional cardiology

Jan Škvařil*, Miroslav Černohous, Martin Hajšl, Pavel Sedloň, Miroslav Zavoral, Martin Malý
Kardiologické oddělení, Interní klinika, 1. lékařská fakulta Univerzity Karlovy a Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha, Praha, Česká republika

Introduction: According to contemporary experience, bioabsorbable vascular scaffolding (BVS) implantation represents promising perspective in cardiology interventions. In the cathlab of Central Military Hospital in Prague, the program of BVS implantation started in June 2013.
Patient cohort and methods: From June 2013 to October 2015, 107 procedures of BVS implantation in 98 patients were performed. Total of 110 lesions were treated. In nine patients BVS was implanted in two stages. In three patients, the intervention of two vessels was performed during one procedure, always using BVS. Non-randomized data of three cohorts of patients were evaluated: STEMI (45 patients), NSTEMI (34 patients), and elective BVS implantations (31 patients). The three groups did not differ in basic demographic features. In STEMI group, initial thrombotic occlusion and consequent thrombaspiration were more often. In this (STEMI) group, the evaluation of the procedure is supplemented by CT performance after 12 months.

Results: The procedure was always technically successful except 1 case (NSTEMI). Residual diameter stenosis >20% was registered in 1 patient in each group. Except 1 case in STEMI group, final TIMI III flow was achieved in all cases. One patient died in NSTEMI group in consequence of definite stent thrombosis. The final angiographic result (recoil, residual stenosis) was evaluated with the aid of quantitative coronary analysis (QCA). It did not prove any statistically significant difference among the groups. The value of immediate recoil did not exceed 10% in all groups. Target Lesion Revascularization (TLR) was performed in two patients in STEMI group. Up to now, performed CT scans demonstrated persisting good results.

Conclusion: In accordance with contemporary literary data, our experience proves safety and efficacy of BVS implantation during coronary interventions in selected patients.

Keywords: Bioabsorbable vascular scaffolding; Elective PCI; Primary PCI; Quantitative coronary analysis

Received: May 22, 2016; Revised: November 10, 2016; Accepted: November 16, 2016; Published: June 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škvařil J, Černohous M, Hajšl M, Sedloň P, Zavoral M, Malý M. Bioabsorbable stents in routine practice. New epoch in interventional cardiology. Cor Vasa. 2017;59(3):e251-256. doi: 10.1016/j.crvasa.2016.11.007.
Download citation

References

  1. Y. Onuma, P.W. Serruys, Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?, Circulation 123 (2011) 779-797. Go to original source... Go to PubMed...
  2. J.A. Ormiston, M.W. Webster, G. Armstrong, First-in-human implantation of fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent, Catheterization and Cardiovascular Interventions 69 (2007) 128-131. Go to original source... Go to PubMed...
  3. M. Otsuka, S. Tanimoto, G. Sianos, et al., "Radio-lucent" and "radioopaque" coronary stents characterized by multislice computed tomography, International Journal of Cardiology 132 (2009) e8-e10. Go to original source... Go to PubMed...
  4. J.A. Ormiston, P.W. Serruys, E. Regar, et al., A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial, Lancet 371 (2008) 899-907. Go to original source... Go to PubMed...
  5. R. Diletti, V. Farooq, C. Girasis, et al., Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial, Heart 99 (2013) 98-105. Go to original source... Go to PubMed...
  6. T. Gori, E. Schulz, U. Hink, et al., Early outcome after implantation of Absorb bioresorbable drug-eluting scaffolds in patients with acute coronary syndromes, EuroIntervention 9 (2014) 1036-1041. Go to original source... Go to PubMed...
  7. V. Kočka, M. Malý, P. Toušek, et al., Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study 'Prague 19', European Heart Journal 35 (2014) 787-794. Go to original source... Go to PubMed...
  8. P.W. Serruys, B. Chevalier, D. Dudek, et al., A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial, Lancet 385 (2015) 43-54. Go to original source... Go to PubMed...
  9. A.J. Brown, L.M. McCormick, D.M. Braganza, et al., Expansion and malapposition characteristics after bioresorbable vascular scaffold implantation, Catheterization and Cardiovascular Interventions 84 (2014) 37-45. Go to original source... Go to PubMed...
  10. C. Costopoulos, A. Latib, T. Naganuma, et al., Comparison of early clinical outcomes between absorb bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population, Catheterization and Cardiovascular Interventions 85 (2015) E10-E15. Go to original source... Go to PubMed...
  11. R. Diletti, A. Karanasos, T. Muramatsu, et al., Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study, European Heart Journal 35 (2014) 777-786. Go to original source... Go to PubMed...
  12. J. Wiebe, H. Möllmann, A. Most, et al., Short-term outcome of patients with ST-segment elevation myocardial infarction (STEMI) treated with an everolimus-eluting bioresorbable vascular scaffold, Clinical Research in Cardiology 103 (2014) 141-148. Go to original source... Go to PubMed...
  13. J. Gómez-Lara, S. Brugaletta, R. Diletti, et al., Agreement and reproducibility of gray-scale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold, Catheterization and Cardiovascular Interventions 79 (2012) 890-902. Go to original source... Go to PubMed...
  14. R. Waksman, H. Kitabata, F. Prati, et al., Intravascular ultrasound versus optical coherence tomography guidance, Journal of the American College of Cardiology 62 (17 Suppl.) (2013) S32-S40. Go to original source... Go to PubMed...
  15. U.K. Allahwala, J.A. Cockburn, E. Shaw, et al., Clinical utility of optical coherence tomography (OCT) in the optimisation of Absorb bioresorbable vascular scaffold deployment during percutaneous coronary intervention, EuroIntervention 10 (2015) 1154-1159. Go to original source... Go to PubMed...
  16. N. Foin, M. Ghione, A. Mattesini, et al., Bioabsorbable scaffold optimization in provisional stenting: insight from optical coherence tomography, European Heart Journal - Cardiovascular Imaging 14 (2013) 1149. Go to original source... Go to PubMed...
  17. E. Alegría-Barrero, N. Foin, P.H. Chan, et al., Optical coherence tomography for guidance of distal cell recrossing in bifurcation stenting: choosing the right cell matters, EuroIntervention 8 (2012) 205-213. Go to original source... Go to PubMed...
  18. P.W. Serruys, Y. Onuma, J.A. Ormiston, et al., Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes, Circulation 122 (2010) 2301-2312. Go to original source... Go to PubMed...
  19. L. Wallentin, R.C. Becker, A. Budaj, et al., Ticagrelor versus clopidogrel in patients with acute coronary syndromes, New England Journal of Medicine 361 (2009) 1045-1057. Go to original source... Go to PubMed...
  20. Y. Onuma, P.W. Serruys, L.E. Perkins, et al., Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the humanoptical coherence tomography images in the ABSORB trial, Circulation 122 (2010) 2288-2300. Go to original source... Go to PubMed...
  21. P.W. Serruys, B. Chevalier, Y. Sotomi, et al., Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3-year, randomized, controlled, single-blind multicenter clinical trial, Lancet 388 (2016) 2479-2491. Go to original source... Go to PubMed...
  22. R. Gao, et al., ABSORB China: Two-year clinical outcomes from a prospective, randomized trial of an everolimus-eluting bioresorbable vascular scaffold vs an everolimus-eluting metallic stent in patients with coronary artery disease, in: TCT 2016, Washington, DC, 30 October 2016, 2016.
  23. G. Caiazzo, I.D. Kilic, E. Fabris, et al., Absorb bioresorbable vascular scaffold: what have we learned after 5 years of clinical experience, International Journal of Cardiology 201 (2015) 129-136. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.